Group 1 - Silver Point Capital initiated a new position in Bausch + Lomb Corporation, acquiring approximately 2.6 million shares valued at around $38.7 million as of the end of the quarter [2][6] - The new stake represents 2.8% of Silver Point's reported assets under management (AUM) as of September 30, indicating a significant investment in Bausch + Lomb [3][8] - Bausch + Lomb's stock price was $16.95, reflecting a 13% decline over the past year, contrasting with the S&P 500's 13% increase during the same period [3][4] Group 2 - Bausch + Lomb operates in the eye health sector, offering a range of products including contact lenses, lens care products, ophthalmic pharmaceuticals, and surgical devices across three segments: Vision Care/Consumer Health Care, Ophthalmic Pharmaceuticals, and Surgical [5] - The company reported a 7% revenue growth to $1.3 billion in the third quarter, with adjusted EBITDA rising to $243 million, while also reaffirming full-year revenue guidance [8] - Despite the revenue growth, Bausch + Lomb experienced a net loss of $28 million compared to a net income of $4 million in the previous year [8]